Showing results (21-30 of 241) with videos related to

Sort By:
Pageof 25
Experimental Hematology|September 28, 2010
Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapySari E Jalkanen, Jukka Vakkila, Anna Kreutzman, et al.
Annals of Medicine|February 12, 2014
Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutationsHanna L M Rajala, Kimmo Porkka, Jaroslaw P Maciejewski, et al.
Pediatric Blood & Cancer|May 11, 2006
Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cellsSanna-Maria Kivivuori, Sanna Siitonen, Kimmo Porkka, et al.
Blood|September 14, 2016
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft modelsHelena Ågerstam, Nils Hansen, Sofia von Palffy, et al.
Cancer|November 20, 2009
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusionKimmo Porkka, H Jean Khoury, Ronald L Paquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib TherapyNoortje Thielen, Johan Richter, Matthias Baldauf, et al.
Cancer Epidemiology|July 17, 2012
Medical registries represent vital patient interests and should not be dismantled by stricter regulationMats G Hansson, Bengt Simonsson, Nils Feltelius, et al.
Lakartidningen|September 27, 2017
[Chronic myeloid leukemia – a model disease for targeted therapy]Johan Richter, Leif Stenke
Duodecim; Laaketieteellinen Aikakauskirja|December 15, 2017
Applications of genomic medicine in the treatment of diseasesKimmo Porkka, Mikko Niemi, Elli Leppä, et al.
Plos One|February 6, 2014
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapyMette Ilander, Anna Kreutzman, Peter Rohon, et al.
Pageof 25